Jan 27, 2012
Magnetic fluid targets insulin-related amyloidosis
Researchers from the Institute of Experimental Physics at the Slovak Academy of Sciences (IEP SAS) in Kosice are investigating the interaction of albumin-modified magnetic fluids with insulin amyloid aggregates. The research tackles complications associated with diabetes, where amyloid deposits (fibrils) can form in patients near the site of insulin injections.
The scientists have looked at the effect of albumin-modified magnetic fluids consisting of magnetite nanoparticles and varying amounts of bovine serum albumin, which can be used to adjust the material's physico-chemical properties (hydrodynamic diameter, zeta potential and isoelectric point).
Results indicate that incubation of insulin amyloid fibrils with albumin-modified magnetic fluid leads to the significant destruction of aggregates. The extent of the depolymerizing activity was affected by the amount of albumin used for magnetic fluid modification and mainly depends on the size of nanoparticles.
The team's findings represent a starting point for the application of active albumin-modified magnetic fluids as therapeutic agents targeting insulin amyloidosis.
More details can be found in the journal Nanotechnology.
About the author
The work was performed at the Department of Biophysics of IEP SAS in Kosice, Slovakia, where Zuzana Gazova, head of the research group, and co-workers (Andrea Antosova, Katarina Siposova, Zuzana Bednarikova and Zuzana Daxnerova) investigate the amyloid aggregation of proteins. Martina Koneracka, Vlasta Zavisova, Peter Kopcansky and Martina Kubovcikova from the Department of Magnetism at IEP SAS supplied nanoparticles for the experiments. This team has great experience in the field of magnetic nanoparticles, magnetic fluids and their composites.